Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 110,331

Document Document Title
WO/2015/128674A1
The present invention relates to quinoline compounds as defined by Formula I below. Such quinoline compounds have been shown to inhibit the formation of amyloid deposits (e.g. amyloid oligomers, fibrils or plaques). Consequently, these c...  
WO/2015/129853A1
 The purpose of the present invention is to provide a novel compound having RORγ antagonist activity, and to provide agents for the treatment or prevention of autoimmune diseases and allergic diseases actualizing a drug effect based o...  
WO/2015/127872A1
The present invention provides a class of 2,4-disubstituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug of said derivati...  
WO/2015/127873A1
Provided are an arylamino pyramidine compound having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvent compound, or prodrug of said arylamino pyramidine compound; also provided are...  
WO/2015/123801A1
Disclosed in the present invention is a preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof. New crystal forms are comprehensively characterized by X-ray powder diffraction, thermogravimetic...  
WO/2015/125752A1
Provided are: a method for chemical detection of a cerebral circulatory disorder at an early stage in a subject; and furthermore, a simple inhibitor which is capable of taking effect early against cerebral circulatory disorders such as n...  
WO/2015/124932A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L,X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositio...  
WO/2015/126434A1
This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average se...  
WO/2015/124934A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L,X, Ra, Rb, R 1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical c...  
WO/2015/126915A3
A β1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a β1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound rela...  
WO/2015/124616A1
The present invention relates to compositions containing, as their only active ingredients, an extract of Curcuma spp, optionally as curcumin in the form of a complex with phospholipids, and an extract selected from Echinacea spp extract...  
WO/2015/126836A2  
WO/2015/124318A1
The present invention relates to an edible composition including safranal, crocin, picrocrocin and a vitamin B complex which includes vitamins B1, B2, B3, B6, B8, B9 and B12; said composition being advantageously intended for treating th...  
WO/2015/124763A1
The present invention relates to compositions and methods for the treatment of the mechanical neuronal insu  
WO/2015/125702A1
This invention provides the following: an antibody that targets the molecule that results when the 65th serine residue in ubiquitin is phosphorylated; a method for early, specific detection of Parkinson's disease that targets the molecul...  
WO/2015/125152A3
The present invention relates to liquid compositions of asenapine with one or more pharmaceutically acceptable excipients. More particularly, the present invention relates to liquid spray compositions comprising asenapine for administrat...  
WO/2015/127037A1
In some embodiments, the present disclosure pertains to a composition for modulating the expression of at least one gene associated with neuronal cell survival or stability. In some embodiments, the present disclosure provides for compos...  
WO/2015/127450A1
The present invention provides compounds and pharmaceutical compositions for treating neurological diseases such as multiple sclerosis.  
WO/2015/124540A1
The invention provides a blood brain barrier shuttle comprising a brain effector entity and a brain targeting peptide.  
WO/2015/127186A1
The present invention features compositions of Tmem100 peptides and variants thereof, and their use in treating or preventing diseases or conditions.  
WO/2015/125842A1
Provided is a compound which has a mPGES-1 inhibitory activity and is useful for the prevention or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hyperten...  
WO/2015/123750A1
Described is a transdermal ethosome composition for the treatment of pain. The transdermal ethosome composition comprises: an alcohol; a phospholipid; water; and a magnesium salt, a TRPV1 receptor agonist, or both a magnesium salt and a ...  
WO/2015/125969A1
The present invention provides: a transdermal liquid preparation which comprises a triptan-type medicine; and a liquid-type adhesive skin patch which is produced by impregnating a resin porous sheet with the transdermal liquid preparatio...  
WO/2015/127451A1
A compound for treatment of pain comprising a single multivalent/multifunctional ligand with agonist activity at opioid receptors and with antagonist activity at NK-1 receptors, joined by a linker. Also disclosed is a pharmaceutical comp...  
WO/2015/123618A1
The present invention provides a method for treating a clinical condition associated with underexpression of BCL2 gene. In particular, the present invention provides a method for treating a clinical condition associated with underexpress...  
WO/2015/123533A1
The present invention provides compounds of formula (I): which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and interm...  
WO/2015/123505A1
The present invention provides compounds of formula (I): [Formula should be entered here] which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes fo...  
WO/2015/121227A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 6,9-disubstituted 2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4, R5, R6a and R...  
WO/2015/122524A1
Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. Thi...  
WO/2015/121218A1
The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death and/or glucose impaired neuronal metabolism. More specifically, the present inventi...  
WO/2015/121268A1
The invention relates to bromodomain protein-inhibiting, in particular BET protein-inhibiting, and preferably BRD4-inhibiting 3H-2,3-benzodiazepines of general formula (I), in which R1a, R1b, R1c, R2, R3, R4 and R5 have the meanings spec...  
WO/2015/121212A1
Compounds of formula (I), wherein Z = cyclopentyl. cyclopropylmethyl, -CH3; R' = -CH3, CHF2, X= formula (II) (III) (IV) (V) Y = - CO; -C=O(CH2), -CH(OH)-CH2, -CH2-C=O, -CH2-CH2-C=O; -CH2-CH(OH)-CH2, -CH2- CH(OCOR1)-CH2 NR2 = -N(CH2-CH2OH...  
WO/2015/121812A1
The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also...  
WO/2015/123398A1
The Invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, or diastereomers thereof: wherein W1, W2, W3, J1, J2, A, R1, R2, R3, R4, R5, a, and b are defined as set forth in the sp...  
WO/2015/118554A1
The disclosure herein provides 1-carbamoyloxyethyl 5-(1,2-dithiolan-3-yl)pentanoate derivatives of formula I, formula II and formula III. The disclosure also provides a method of synthesizing the compound of formula I, formula II and for...  
WO/2015/120317A1
New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.  
WO/2015/118026A1
The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R'" but may not be a quaternary C atom; R' is -OR1, -CONH2, -CF3, F, -OH, -NO2, -CN or -OCO...  
WO/2015/119126A1
The purpose of the present invention is to provide a novel compound having a selective JAK3-inhibiting effect and excellent oral absorption. Moreover, the purpose of the present invention is to provide a medical drug useful, on the basis...  
WO/2015/118019A1
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/119111A1
The problem addressed by the present invention is to provide an anti-prion compound having high crystallinity and high crystal stability, and to provide an agent for the prevention, amelioration, and treatment of prion disease. The prese...  
WO/2015/120280A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patien...  
WO/2015/120203A1
The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject, comprising administering to the subject an effective amount of a compound comprising ghrelin.  
WO/2015/120434A1
Described herein are nieihods for the prevention of neurodegeneratiori and the treatment of ncwodegenerati ve disease (Including amyotrophic lateral sclerosis) ami tieurodeveiopmetifal disorders through the administration of an agent tha...  
WO/2015/120233A1
Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.  
WO/2015/118019A9
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/120446A1
In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some...  
WO/2015/120038A1
The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-rnediated events following a brain injury or long-term neuroinflammat...  
WO/2015/118363A1
The present invention relates to a food supplement comprising L-tryptophan and vitamins from the B vitamins group, to pharmaceutical compositions containing said food supplement and to the production process of said food supplement.  
WO/2015/119998A1
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or am...  
WO/2015/113169A1
Provided herein are humanized antibodies or antigen-binding fragments thereof, that can bind to a cyclic peptide comprising the amino acid sequence SNK, wherein the K (Lysine) is solvent-accessible and methods of treating and/or preventi...  

Matches 701 - 750 out of 110,331